Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Topotecan + Veliparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Topotecan||Hycamtin||Topotecan Hcl||Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary).|
|Veliparib||ABT-888||PARP Inhibitor (Pan) 19||Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Topotecan + Veliparib||Phase I||Actionable||In a Phase I trial, the combination of Veliparib (ABT-888) and topotecan demonstrated safety and tolerability, and resulted in an objective response rate of 10% (5/51; 1 complete response and 4 partial responses) and stable disease for at least 4 months in 43% (22/51) of patients with advanced solid tumors, with the majority of the patients having ovarian, fallopian tube, or primary peritoneal cancer (PMID: 29138343; NCT01012817).||29138343|
|Unknown unknown||ovarian carcinoma||not applicable||Topotecan + Veliparib||Phase I||Actionable||In a Phase I trial, the combination of Veliparib (ABT-888) and topotecan demonstrated safety and tolerability, and resulted in an objective response rate of 9% (4/45; 1 complete response and 3 partial responses) and stable disease in 21 patients with ovarian carcinoma (PMID: 29138343; NCT01012817).||29138343|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01012817||Phase Ib/II||Topotecan + Veliparib||Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer||Active, not recruiting|